VKH
NTLA icon

Virtu KCG Holdings’s Intellia Therapeutics NTLA Stock Holding History

Virtu KCG Holdings’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$203K Buy
+12,697
New +$177K 0.01% 2148
2017
Q1 		– Sell
-20,545
Closed -$269K – 3546
2016
Q4 		$269K Buy
+20,545
New +$309K 0.01% 2232

Other funds holding NTLA

AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Virtu KCG Holdings's NTLA Position: Q2 2017 in Review

Virtu KCG Holdings opened a new position in Intellia Therapeutics (NTLA) in Q2 2017: 12,697 shares worth $203K. The stake represents 0.01% of the portfolio and ranks #2148 among its holdings. This is a return to the name: Virtu KCG Holdings previously reported a position in NTLA as recently as Q4 2016.

Virtu KCG Holdings first reported a position in NTLA in Q4 2016 and has held it in 2 quarters since. The position peaked at $269K in Q4 2016. 85 funds tracked by Wall St. Rank hold NTLA as of Q2 2017.

  • Virtu KCG Holdings held 12,697 shares of Intellia Therapeutics worth $203K as of Q2 2017.
  • Intellia Therapeutics was a new Virtu KCG Holdings position in Q2 2017.
  • Intellia Therapeutics made up 0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #2148 holding.
  • Virtu KCG Holdings first reported a position in Intellia Therapeutics in Q4 2016 and has held it in 2 quarters since.
  • Virtu KCG Holdings's Intellia Therapeutics position peaked at $269K in Q4 2016.
  • 85 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.